vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and ENERPAC TOOL GROUP CORP (EPAC). Click either name above to swap in a different company.

ENERPAC TOOL GROUP CORP is the larger business by last-quarter revenue ($144.2M vs $77.6M, roughly 1.9× Bioceres Crop Solutions Corp.). ENERPAC TOOL GROUP CORP runs the higher net margin — 13.3% vs -9.6%, a 22.9% gap on every dollar of revenue. On growth, ENERPAC TOOL GROUP CORP posted the faster year-over-year revenue change (-0.7% vs -16.8%). Over the past eight quarters, ENERPAC TOOL GROUP CORP's revenue compounded faster (2.1% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Enerpac Tool Group Corp., formerly Actuant Corporation, was founded in 1910 and is headquartered in Menomonee Falls, Wisconsin. Enerpac Tool Group common stock trades on the NYSE under the symbol EPAC.

BIOX vs EPAC — Head-to-Head

Bigger by revenue
EPAC
EPAC
1.9× larger
EPAC
$144.2M
$77.6M
BIOX
Growing faster (revenue YoY)
EPAC
EPAC
+16.1% gap
EPAC
-0.7%
-16.8%
BIOX
Higher net margin
EPAC
EPAC
22.9% more per $
EPAC
13.3%
-9.6%
BIOX
Faster 2-yr revenue CAGR
EPAC
EPAC
Annualised
EPAC
2.1%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
EPAC
EPAC
Revenue
$77.6M
$144.2M
Net Profit
$-7.4M
$19.1M
Gross Margin
46.8%
50.7%
Operating Margin
9.3%
19.8%
Net Margin
-9.6%
13.3%
Revenue YoY
-16.8%
-0.7%
Net Profit YoY
-20.2%
-11.9%
EPS (diluted)
$-0.12
$0.36

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
EPAC
EPAC
Q4 25
$144.2M
Q3 25
$77.6M
$167.5M
Q2 25
$158.7M
Q1 25
$60.6M
$145.5M
Q4 24
$98.8M
$145.2M
Q3 24
$93.3M
$158.7M
Q2 24
$150.4M
Q1 24
$84.0M
$138.4M
Net Profit
BIOX
BIOX
EPAC
EPAC
Q4 25
$19.1M
Q3 25
$-7.4M
$28.1M
Q2 25
$22.0M
Q1 25
$-1.6M
$20.9M
Q4 24
$605.2K
$21.7M
Q3 24
$-6.2M
$24.4M
Q2 24
$25.8M
Q1 24
$9.8M
$17.8M
Gross Margin
BIOX
BIOX
EPAC
EPAC
Q4 25
50.7%
Q3 25
46.8%
50.1%
Q2 25
50.4%
Q1 25
39.4%
50.5%
Q4 24
42.0%
51.4%
Q3 24
40.2%
48.8%
Q2 24
51.8%
Q1 24
50.8%
51.6%
Operating Margin
BIOX
BIOX
EPAC
EPAC
Q4 25
19.8%
Q3 25
9.3%
23.8%
Q2 25
20.0%
Q1 25
1.5%
21.2%
Q4 24
14.5%
21.4%
Q3 24
2.5%
18.9%
Q2 24
22.2%
Q1 24
15.7%
21.3%
Net Margin
BIOX
BIOX
EPAC
EPAC
Q4 25
13.3%
Q3 25
-9.6%
16.8%
Q2 25
13.9%
Q1 25
-2.6%
14.4%
Q4 24
0.6%
15.0%
Q3 24
-6.6%
15.4%
Q2 24
17.1%
Q1 24
11.6%
12.9%
EPS (diluted)
BIOX
BIOX
EPAC
EPAC
Q4 25
$0.36
Q3 25
$-0.12
$0.51
Q2 25
$0.41
Q1 25
$-0.02
$0.38
Q4 24
$0.00
$0.40
Q3 24
$-0.10
$0.44
Q2 24
$0.47
Q1 24
$0.14
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
EPAC
EPAC
Cash + ST InvestmentsLiquidity on hand
$15.5M
$139.0M
Total DebtLower is stronger
$188.8M
Stockholders' EquityBook value
$288.3M
$431.1M
Total Assets
$734.9M
$818.1M
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
EPAC
EPAC
Q4 25
$139.0M
Q3 25
$15.5M
$151.6M
Q2 25
$140.5M
Q1 25
$38.5M
$119.5M
Q4 24
$29.2M
$130.7M
Q3 24
$32.3M
$167.1M
Q2 24
$132.4M
Q1 24
$16.4M
$153.7M
Total Debt
BIOX
BIOX
EPAC
EPAC
Q4 25
$188.8M
Q3 25
$190.0M
Q2 25
$191.3M
Q1 25
$192.5M
Q4 24
$193.8M
Q3 24
$195.0M
Q2 24
$196.3M
Q1 24
$245.5M
Stockholders' Equity
BIOX
BIOX
EPAC
EPAC
Q4 25
$431.1M
Q3 25
$288.3M
$433.7M
Q2 25
$438.2M
Q1 25
$345.0M
$406.0M
Q4 24
$346.3M
$398.0M
Q3 24
$346.0M
$392.0M
Q2 24
$365.8M
Q1 24
$348.5M
$336.9M
Total Assets
BIOX
BIOX
EPAC
EPAC
Q4 25
$818.1M
Q3 25
$734.9M
$827.9M
Q2 25
$828.1M
Q1 25
$798.2M
$776.6M
Q4 24
$835.2M
$775.4M
Q3 24
$827.3M
$777.3M
Q2 24
$749.5M
Q1 24
$836.1M
$769.3M
Debt / Equity
BIOX
BIOX
EPAC
EPAC
Q4 25
0.44×
Q3 25
0.44×
Q2 25
0.44×
Q1 25
0.47×
Q4 24
0.49×
Q3 24
0.50×
Q2 24
0.54×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
EPAC
EPAC
Operating Cash FlowLast quarter
$14.4M
$16.0M
Free Cash FlowOCF − Capex
$13.3M
FCF MarginFCF / Revenue
9.2%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.84×
TTM Free Cash FlowTrailing 4 quarters
$102.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
EPAC
EPAC
Q4 25
$16.0M
Q3 25
$14.4M
$55.3M
Q2 25
$39.9M
Q1 25
$23.3M
$7.5M
Q4 24
$-5.4M
$8.6M
Q3 24
$5.2M
$44.4M
Q2 24
$30.3M
Q1 24
$-17.4M
$13.3M
Free Cash Flow
BIOX
BIOX
EPAC
EPAC
Q4 25
$13.3M
Q3 25
$52.3M
Q2 25
$35.1M
Q1 25
$1.8M
Q4 24
$2.8M
Q3 24
$37.9M
Q2 24
$28.5M
Q1 24
$11.7M
FCF Margin
BIOX
BIOX
EPAC
EPAC
Q4 25
9.2%
Q3 25
31.2%
Q2 25
22.1%
Q1 25
1.2%
Q4 24
1.9%
Q3 24
23.9%
Q2 24
18.9%
Q1 24
8.5%
Capex Intensity
BIOX
BIOX
EPAC
EPAC
Q4 25
1.9%
Q3 25
1.8%
Q2 25
3.1%
Q1 25
3.9%
Q4 24
4.0%
Q3 24
4.1%
Q2 24
1.2%
Q1 24
1.1%
Cash Conversion
BIOX
BIOX
EPAC
EPAC
Q4 25
0.84×
Q3 25
1.97×
Q2 25
1.81×
Q1 25
0.36×
Q4 24
-8.85×
0.40×
Q3 24
1.82×
Q2 24
1.18×
Q1 24
-1.78×
0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

EPAC
EPAC

Transferred At Point In Time$126.0M87%
Other$12.1M8%
Other Operating Segment$6.1M4%

Related Comparisons